Disease bulk is an important prognostic factor in early stage Hodgkin lymphoma, but its definition is unclear in the computed tomography-era. This retrospective analysis investigated the prognostic significance of bulky disease measured in transverse and coronal planes on computed tomography imaging. Early stage Hodgkin lymphoma patients (n=185) treated with chemotherapy with or without radiotherapy from 2000-2010 were included. The longest diameter of the largest lymph node mass was measured in transverse and coronal axes on pre-treatment imaging. The optimal cutoff for disease bulk was maximal diameter greater than 7 cm measured in either the transverse or coronal plane. Thirty patients with maximal transverse diameter ≤ 7 cm were found to have bulk in coronal axis. The 4-year overall survival was 96.5% (CI 93.3%, 100%) and 4-year relapse-free survival was 86.8% (CI 81.9%, 92.1%) for all patients. Relapse free survival at 4-years for bulky patients was 80.5% (CI 73%, 88.9%) compared to 94.4% (CI 89.1%, 100%) for non-bulky, Cox HR 4.21 (CI 1.43, 12.38), P = 0.004. In bulky patients, relapse free survival was not impacted in patients treated with chemoradiotherapy; however, was significantly inferior in patients treated with chemotherapy alone. In an independent validation cohort of 38 patients treated with chemotherapy alone, patients with bulky disease had an inferior relapse-free survival (at 4-years, 71.1% (CI 52.1%, 97%) versus 94.1% (CI 83.6%, 100%), Cox HR 5.27 (CI 0.62, 45.16), P = 0.09). Presence of bulky disease on multidimensional computed tomography imaging is a significant prognostic factor in early stage Hodgkin lymphoma. Coronal reformations may be included for routine Hodgkin lymphoma staging evaluation. In future, our definition of disease bulk may have utility in identifying patients who are most appropriate for chemotherapy-alone.
Introduction
The presence of bulky disease at presentation has long been considered a poor prognostic factor in early stage Hodgkin lymphoma (ESHL).
1, 2 Historically, bulk in the mediastinum was focused upon and defined using radiographic criteria from a standing posterior-anterior (PA) chest radiograph (CXR). In the 1989 Cotswolds revision of the Ann Arbor Staging system bulk in the mediastinum was defined as, "when the maximum width is equal or greater than one-third of the internal transverse diameter of the thorax at the level of T5/6" on a PA CXR and bulk at an alternate site was defined as any mass measuring ≥ 10 cm by any imaging study. 3 Today the presence of bulky disease in ESHL remains an unfavorable prognostic feature in all modern risk classification systems, but is variably defined as >1/3 of the mediastinal mass ratio (MMR), >1/3 of the mediastinal thoracic ratio (MTR), or any mass >10 cm. [4] [5] [6] [7] Although definitions of disease bulk were originally developed in the CXR-era, computed tomography (CT) imaging is now the standard staging imaging modality in lymphoma. 8 In the CT era, the definition of disease bulk remains elusive. Various retrospective studies have defined CT criteria for bulky disease associated with increased risk of relapse in ESHL, ranging from greater than 5 to 10 cm for the maximal mediastinal mass diameter in transverse plane. [9] [10] [11] The recent "Lugano Classification" for initial staging in lymphoma retains the historical definition of bulk with a single nodal mass of ≥ 10 cm or mediastinal bulk >1/3 of the transthoracic diameter.
However, with uncertainty regarding an evidence-based definition of bulk in the CT-era, the authors also suggest elimination of the modifier "X" and propose recording the longest measurement by CT scan, presumably in the transverse plane. 8 However, there remains a critical need for a bulky disease cut-point in ESHL as increasingly patients are being treated with chemotherapy alone to avoid the late-effects of radiotherapy, an approach that has generally excluded patients with disease bulk. 12, 13 For example, the recently published UK RAPID study included stage IA and IIA patients without mediastinal bulk defined as maximal mediastinal diameter ≥ 33% of the internal thoracic diameter at T5-T6. 12 Importantly, the transverse diameter of a lymph node mass may not reflect the longest dimension of an obliquely or sagittally positioned mass in HL. On CT, lymph node masses can be measured in the transverse, coronal, and sagittal planes, however, measurements in axes other than the transverse are rarely reported in HL, and 3-dimensional or volumetric assessments of tumor bulk are difficult to routinely assess. In this study, we aimed to assess the prognostic significance of the longest diameter of the largest nodal mass measured in either the transverse and coronal planes using CT imaging.
Methods

Patients
For the training cohort of this retrospective study, we identified pediatric and adult December 2010 were included. These retrospective analyses were conducted on waivers of authorization approved by the institutional review boards at each institution.
Radiologic Assessment
Measurements for the training cohort were performed by a single board-certified radiologist (I.B.) who was blinded to patients' clinical history, including treatment and outcome.
All available pretreatment imaging studies, including diagnostic computed tomography (dCT), Figure 1 ). This measurement could lie obliquely, or in any orientation, to ensure ascertainment of the maximal diameter. Coronal images were analyzed and reformatted using the open-source software
OsiriX. 14 The quality of the coronal reconstruction was dependent on the slice thickness, ranging from 1.2 to 7.5 mm. The quality of coronal reconstructions was assessed using a subjective scale:
0-poor, 1-fair, 2-good.
For the validation cohorts, the measurements were performed in a similar manner as described for the training cohort. At DFCI, the measurements were performed by a single medical oncologist (A.K.) and at Mayo by a single board-certified radiologist (D.W.), both blinded to patient outcome. Coronal reconstructions were created using OsiriX and TeraRecon (TeraRecon, Inc.) software at DFCI (n=25) and at Mayo (n=13), respectively. Measurements were made from dCT at baseline (23 of 38, 61%) and low-dose CT in conjunction with FDG-PET imaging (15 of 38, 39%).
Statistical analysis
Survival analyses were performed using the Kaplan-Meier method in SPSS 22 and R 3.2.3. Relapse-free survival (RFS) and overall survival (OS) were defined as the time from initiation of treatment until progression of disease or relapse (RFS) or until death from any cause (OS), respectively. Log-rank tests were used to compare survival differences. A p-value of ≤ 0.05 was considered statistically significant.
The Pearson correlation test assessed the degree of correlation between the maximal transverse and coronal diameters. With few deaths, only the association between disease bulk and RFS was assessed. To identify the optimal cutoff for the transverse and coronal maximal diameters to predict outcome, we identified a range of potential cutoff points (in cm) based upon the distribution of the data (between the 10 th and 90 th percentiles), and examined their significance levels using log-rank tests correlating with RFS. The cutoff point resulting in the maximal significance level was identified as the optimal cutoff for the transverse and coronal dimensions, and this p-value was adjusted by the maximal chi-square method since multiple tests were performed. 15 Further, we aimed to identify the most predictive "combined" criterion. By using concordance probability analysis, we identified the set of maximal diameter cutoffs (i.e.
transverse > X OR coronal > Y) that most strongly predicted RFS. 16 The methods for determining bulky disease cutoff, including maximal chi-square method and concordance probability analysis, are described in detail in the Supplement.
Results
In total, there were 185 patients who met inclusion criteria for this study. Of the 185 images examined, 158 (85%) were characterized by the interpreting radiologist as good quality for coronal measurement assessment and 27 fair quality (15% All patients were treated with standard or novel doxorubicin-based chemotherapy regimens ( Table 1 ). The vast majority of patients were treated with ABVD or Stanford V, and others were treated with various doxorubicin-containing regimens, including clinical trial protocols. A proportion of CD20+ HL patients were treated with rituximab-containing regimens (6 of 16). One hundred and fifteen patients (62%) were treated with combined modality therapy (CMT) and 70 patients (38%) with chemotherapy alone.
Outcomes
Of the 185 patients, 23 patients relapsed and 6 patients died after initial therapy (4 deaths due to progressive HL after multiple lines of salvage treatment, 1 death from secondary MDS, and 1 death of unknown cause). The median follow-up for all patients was 5 years. The 4-year OS was 96.5% (CI 93.2%, 100%) and the 4-year RFS was 86.8% (CI 81.8%, 92.1%).
Disease Bulk
Training Cohort
In most cases the longest diameter in the transaxial and coronal plane was measured from the same lymph node mass; however, in 13 cases the longest diameters were from different sites.
In univariate analyses, both transverse maximal diameter and coronal maximal diameter were significantly associated with RFS, see Supplement Table S1 . Using log-rank tests to compare RFS, the optimal cutoff point for transverse maximal diameter was 7 cm (P = 0.01, after adjustment by the maximal chi-square method P = 0.02). The optimal cutoff point for coronal max diameter was 10.5 cm (P = 0.005, after adjustment P = 0.007). Using the concordance probability technique to determine optimal combined criterion, the criteria of transverse max diameter > 7.0 cm OR coronal max diameter > 7.0 cm was the best predictor for progression (see Supplement). Figure 2 demonstrates that the transverse and coronal maximal diameters are highly correlated (correlation coefficient R = 0.856, P < 0.001).
Using cut-point of > 7cm in maximal transverse dimension or maximal coronal dimension (>7cm in MTD or MCD), approximately half of the patients are defined as bulky (101 of 187, 54%). Seventy-three patients had disease bulk > 7.0 cm by transverse criteria and 10 of these patients had disease bulk in the transverse plane alone without disease bulk in the coronal plane. Ninety-one patients had disease bulk > 7.0 cm by coronal criteria with 28 patients identified as having disease bulk > 7.0 cm on coronal imaging that was not appreciated in the transaxial plane. Of the 101 patients with bulky disease (>7cm in MTD or MCD), 83 patients had evidence of mediastinal disease bulk, 17 with other sites of supradiaphragmatic bulk, and 1 with infradiaphragmatic disease bulk, Table 2 .
Univariate analyses for RFS demonstrated that disease bulk defined as >7cm was associated with increased risk for relapse, with similar findings for transverse versus coronal plane measurements and for mediastinal versus non-mediastinal disease, Table 2 Figure S1 ).
Validation Cohort
The novel MSK definition of disease bulk (>7cm in MTD or MCD) was prognostically relevant among patients who received chemotherapy alone, and, therefore, this prognostic factor was examined in an independent validation set of 38 patients with stage II disease treated with chemotherapy alone (36 with 4-6 cycles of ABVD, 1 with 4 cycles of BCVPP, and 1 with 3 cycles of MOPP and 3 cycles of ABVD). The median follow-up was 4 years for this cohort.
Nineteen patients (50%) had disease bulk and 5 patients (13%) were identified to have disease bulk on coronal measurement, but not by transverse measurement. Among the 38 patients, there were 6 relapse events and 2 deaths, 1 undifferentiated sarcoma 8 years post-treatment in a 53-year old and 1 bleomycin-related respiratory failure in a 67 year old. Both deaths occurred in patients with non-bulky disease. Disease bulk was associated with a trend toward inferior RFS, in bulky patients 4-year RFS was 71.1% (CI 52.1%, 97%) versus 4-year RFS of 94.1% (CI 83.6%, 100%) in non-bulky patients (Cox HR 5.27 (CI 0.62, 45.16), P = 0.09), Figure 5 .
Discussion
The importance of reexamining the definition of bulk is based upon improved multidimensional CT data quality and evolving treatment strategies, including reduction and elimination of radiotherapy. Previous definitions of disease bulk were formulated in the era when combined modality therapy was the standard of care for all ESHL patients. 17 Our proposed definition of disease bulk (>7cm in transverse or coronal plane) has heightened prognostic relevance for patients treated with chemotherapy alone. To our knowledge, this is the first study to analyze the prognostic significance of bulky disease defined in both transverse and coronal planes in the era of CT imaging. This study demonstrates that bulky disease when measured in the coronal plane is significantly associated with inferior outcome.
The early stage risk classification systems including GHSG, EORTC, NCIC, and NCCN use MMR and MTR to define mediastinal bulky disease, however, in modern clinical practice and in clinical trials, bulky disease is often defined by the maximal transverse diameter of the largest lymph node mass >10 cm, likely because this measurement is a quick and reproducible method of assessing disease bulk on CT imaging. Other studies have suggested alternate definitions of mediastinal bulky disease, including lymph node masses greater than 5 cm, 6cm, or 7.5 cm. 9, 10, 17, 18 Herein the optimal criterion for bulky disease of >7cm in MTD or MCD falls within the range of previously reported CT bulk definitions. Our data shows that bulky disease in any location, in the mediastinum or an alternate site, is of prognostic value.
Coronal and sagittal reformations in CT studies provide additional diagnostic and clinical information in various clinical settings. 19, 20 Evaluation of coronal images in HL is important for disease bulk positioned obliquely in the mediastinum or for conglomerate lymph node mass extending along the cranio-caudal axis, such as involvement of contiguous cervical, supraclavicular, and infraclavicular lymph nodes. We found additional patients (approximately 30%) with bulky disease were identified using CT coronal reformations that would not have otherwise been identified using transaxial imaging alone, identifying additional patients at increased risk of relapse. Importantly, patients with coronal-only bulk had similar outcomes when compared to patients with bulky disease defined traditionally using transverse measurements. This data has the potential to add to the "Lugano classification" system by clarifying the importance of measuring disease bulk in the coronal axis in addition to the transverse axis.
OsiriX software was used to create coronal reformats from transaxial CT images in this study, however, coronal and sagittal reformations are a routine component of modern multiplanar CT protocols. Obtaining these measurements on modern pretreatment staging CT scans can be easily performed in routine practice. A limitation of this study is that interim and end-of-treatment PET scans were not routinely available. Preliminary data from British Columbia Cancer Agency reports excellent outcomes for bulky HL patients who achieve a negative PET scan after full-course ABVD without additional consolidative RT and there is an ongoing CALGB/Alliance 50801 study exploring interim PET-based risk-adapted therapy in HL patients with disease bulk. 27 These studies will further clarify whether achievement of an interim or end-of-treatment PET may overcome the negative prognostic value of disease bulk at initial presentation. Also the current study was inadequately powered to assess association with OS due to few deaths. Furthermore, due to a limited number of patients and events, subset analyses were underpowered and predominantly univariate analyses were performed. We hope future studies in larger data sets can provide external validation.
In conclusion, our study demonstrates that measurement of bulky disease on coronal reformations in addition to standard transaxial measurements identifies additional patients with disease bulk, and our data suggests that these patients are potentially at increased risk of relapse when treated with chemotherapy alone versus combined modality therapy. Identifying the optimal cutoff of transverse and coronal max diameters for RFS (separately):
Supplement Methodology for Determining Optimal Cutoff for Disease Bulk in Early Stage Hodgkin Lymphoma
Due to the small number of deaths (only 6 in total), we do not use overall survival time but only RFS time. Previous studies have variably defined tumor bulk as a prognostic indicator, ranging from 5-10cm. Based on the previous results and quantiles of the data (we insist that the cut-off points are between the 10 th and 90 th percentiles), we pre-determine some cut-off points for either transverse or coronal max diameters (see table below). We examine their significance levels using log-rank tests (for correlating with RFS).
Of note, we used a Cox proportional hazards model and log-rank tests to correlate various cut-off points with RFS. We did not use ROC analysis which requires a dichotomous endpoint. That is, whether or not patient developed progression at a fixed time point (i.e. 4-year RFS). We sought to examine the time to relapse, which includes not only the event status, but also when the event occurred. Therefore, a Cox proportional hazards model was used, not a ROC analysis.
The cut-off point resulting in the maximal significance level (i.e., smallest p-value) will be identified as the optimal cut-off, whose p-value will also be adjusted by the maximal chi-square method due to the fact that we have looked at multiple tests. 1 We see that the optimal cutoff point for transverse max diameter is 7·0 which yields a p-value of 0·025. After the adjustment this p-value is around 0.046. The optimal cutoff point for coronal max diameter is 10·5 which yields a p-value of 0·0092. After the adjustment this p-value is around 0·014. Note that for the coronal max diameter several other cut-off points give close p-values: 6·0, 6·5, 7·0, 9·5, 11.5 and 12·0. As a matter of fact, if we use the concordance probability (reference 2) instead of the log-rank test p-value to identify the cut-off points, 7·0 will still be the optimal choice for transverse max diameter, but for coronal max diameter 4.5 through 8.5 and 9.5are better than 10·5. This implies that an optimal cut-off point for coronal max diameter cannot be determined clearly statistically, and several options are available. 3·0  0·938  168  4·0  0·208  161  3·5  0·535  152  4·5  0·151  147  4·0  0·766  148  5·0  0·126  136   4·5   0·482  133  5·5  0·066  130  5·0  0·177  121  6·0  0·017  119  5·5  0·332  111  6·5  0·015  109  6·0  0·121  100  7·0  0·012  91  6·5  0·070  88  7·5  0·066  80  7·0  0·025  73  8·0  0·091  75  7·5  0·055  57  8·5  0·054  64  8·0  0·081  46  9·0  0·112  55  8·5  0·174  37  9·5  0·019  45  9·0  0·086  33  10·0  0·034  41  9·5  0·062  26  10·5  0·0092  36  11·0  0·042  30  11·5  0·016  27  12·0 0·0094 20
Seeking for a "combined" criterion:
We combined the two diameters (transverse and coronal) and identify a better predictor. Although 7·0 and 10·5 have been identified as the optimal cut-off points individually, their combination may not be the best in terms of the predictive capacity (as mentioned above, 10·5 for coronal max diameter, though having the smallest log-rank p-value, does not even provide the best predictive capacity separately). Therefore we look at several options in case there exist better predictor than "Transverse > 7·0 OR Coronal > 10·5". The table below shows the findings. Note that here the predictive capacity is evaluated quantitatively by the concordance probability. 
